CStone Pharmaceuticals
PH4
Company Profile
Business description
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
Contact
218 Xinghu Street
C1 Building, North Block
Suzhou Industrial Park
Suzhou215123
CHNT: +86 51287186550
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
stocks
Chart of the Week: Are US mega-cap stocks undervalued?
Opportunities emerge across US equities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.20 | 84.80 | -0.91% |
| CAC 40 | 8,319.87 | 142.52 | -1.68% |
| DAX 40 | 26,367.24 | 81.28 | 0.31% |
| Dow JONES (US) | 53,569.44 | 105.56 | 0.20% |
| FTSE 100 | 10,792.54 | 85.58 | -0.79% |
| HKSE | 25,565.74 | 87.23 | -0.34% |
| NASDAQ | 26,541.35 | 411.15 | 1.57% |
| Nikkei 225 | 66,131.98 | 130.18 | -0.20% |
| NZX 50 Index | 13,880.05 | 133.16 | -0.95% |
| S&P 500 | 7,730.99 | 55.29 | 0.72% |
| S&P/ASX 200 | 9,038.20 | 78.20 | -0.86% |
| SSE Composite Index | 3,956.57 | 44.05 | 1.13% |